Inflarx NV at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
Alright. Welcome, everyone, to the 30th Annual Healthcare Conference of Credit Suisse. I'm Tiago Fauth. I'm biotech analyst here at Credit Suisse and we're joined today by the InflaRx for a fireside chat. Feel free to e-mail me any questions that you might have, and I'll try to work those in, but we can probably get started. As usual, we start with an introduction, kind of key highlights of 2021, where the company is, and then we can dive into some more detailed questions but I don't know, Niels, if you want to just take it away and give a brief overview and all that has changed with InflaRx in the last year or so.
Absolutely. First of all, Jake, thanks so much for inviting us to your conference. We are very happy to be here and speak about InflaRx today. I have with me Thomas Taapken, our CFO; and Jordan Zwick, our Chief Strategy Officer. The question was, let's go into what happened
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |